Gilead Sciences FY2024 EPS Estimate Lifted by Zacks Research

Gilead Sciences, Inc. (NASDAQ:GILD) – Zacks Research raised their FY2024 earnings per share estimates for Gilead Sciences in a note issued to investors on Wednesday, November 20th. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutical company will post earnings per share of $4.26 for the year, up from their prior estimate of $3.73. The consensus estimate for Gilead Sciences’ current full-year earnings is $4.38 per share. Zacks Research also issued estimates for Gilead Sciences’ Q4 2024 earnings at $1.55 EPS, Q1 2025 earnings at $1.62 EPS, Q3 2025 earnings at $1.87 EPS, Q4 2025 earnings at $1.70 EPS, FY2025 earnings at $6.91 EPS, Q1 2026 earnings at $1.55 EPS, Q2 2026 earnings at $1.75 EPS and FY2026 earnings at $7.44 EPS.

Several other equities research analysts have also weighed in on the company. Mizuho lifted their price target on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Thursday. Leerink Partnrs raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Truist Financial increased their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, November 8th. BMO Capital Markets boosted their price objective on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Finally, Daiwa America raised shares of Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Twelve research analysts have rated the stock with a hold rating, eleven have given a buy rating and four have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $95.41.

Gilead Sciences Stock Up 0.5 %

Shares of Gilead Sciences stock opened at $90.19 on Monday. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences has a 12-month low of $62.07 and a 12-month high of $98.90. The company has a market cap of $112.40 billion, a P/E ratio of 1,002.11, a PEG ratio of 2.78 and a beta of 0.17. The company’s fifty day simple moving average is $87.43 and its two-hundred day simple moving average is $76.95.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.29 earnings per share.

Hedge Funds Weigh In On Gilead Sciences

Institutional investors have recently bought and sold shares of the business. Manning & Napier Advisors LLC purchased a new stake in Gilead Sciences during the 2nd quarter valued at $25,328,000. Legal & General Group Plc raised its stake in shares of Gilead Sciences by 0.8% in the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock valued at $851,743,000 after acquiring an additional 93,068 shares during the period. IRON Financial LLC bought a new stake in shares of Gilead Sciences in the 3rd quarter worth about $830,000. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Gilead Sciences by 13.1% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock worth $19,630,000 after purchasing an additional 33,162 shares during the period. Finally, Cetera Investment Advisers grew its holdings in Gilead Sciences by 127.6% during the 1st quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company’s stock valued at $15,668,000 after purchasing an additional 119,909 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 27.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now directly owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. The trade was a 1.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 56,947 shares of company stock valued at $4,968,674 over the last ninety days. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be paid a $0.77 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.42%. Gilead Sciences’s payout ratio is presently 3,422.22%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.